Pfizer agrees to update Chantix warnings

Share this article:

Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters